{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:10:49Z","timestamp":1771002649550,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10620-017-4695-7","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T10:07:51Z","timestamp":1501754871000},"page":"2258-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger\u2013Ellison Syndrome"],"prefix":"10.1007","volume":"62","author":[{"given":"Aaron H.","family":"Mendelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Donowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"4695_CR1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00000658-195510000-00015","volume":"142","author":"RM Zollinger","year":"1955","unstructured":"Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:705\u2013722.","journal-title":"Ann Surg"},{"key":"4695_CR2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.dld.2010.11.007","volume":"43","author":"CM Wilcox","year":"2011","unstructured":"Wilcox CM, Seay T, Arcury JT, Mohnen J, Hirschowitz BI. Zollinger\u2013Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis. 2011;43:439\u2013443.","journal-title":"Dig Liver Dis"},{"key":"4695_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00005792-200011000-00004","volume":"79","author":"PK Roy","year":"2000","unstructured":"Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger\u2013Ellison syndrome. Clinical presentation in 261 patients. Medicine. 2000;79:379\u2013411.","journal-title":"Medicine"},{"key":"4695_CR4","volume-title":"Sleisenger and Fordtran\u2019s gastrointestinal and liver disease: pathophysiology\/diagnosis\/management","author":"M Feldman","year":"2015","unstructured":"Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran\u2019s gastrointestinal and liver disease: pathophysiology\/diagnosis\/management. 10th ed. Philadelphia: Saunders; 2015.","edition":"10"},{"key":"4695_CR5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11894-004-0067-5","volume":"6","author":"F Gibril","year":"2004","unstructured":"Gibril F, Jensen RT. Zollinger\u2013Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454\u2013463.","journal-title":"Curr Gastroenterol Rep"},{"key":"4695_CR6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2013-0369","volume":"19","author":"I Epelboym","year":"2014","unstructured":"Epelboym I, Mazeh H. Zollinger\u2013Ellison syndrome: classical considerations and current controversies. Oncologist. 2014;19:44\u201350.","journal-title":"Oncologist"},{"key":"4695_CR7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","volume":"135","author":"DC Metz","year":"2008","unstructured":"Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469\u20131492.","journal-title":"Gastroenterology"},{"key":"4695_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yasu.2013.02.004","volume":"47","author":"GW Krampitz","year":"2013","unstructured":"Krampitz GW, Norton JA. Current management of the Zollinger\u2013Ellison syndrome. Adv Surg. 2013;47:59\u201379.","journal-title":"Adv Surg"},{"key":"4695_CR9","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3748\/wjg.v18.i39.5495","volume":"18","author":"I Tetsuhide","year":"2012","unstructured":"Tetsuhide I, Cadiot G, Jensen RT. Diagnosis of Zollinger\u2013Ellison syndrome: increasingly difficult. World J Gastroenterol. 2012;18:5495\u20135503.","journal-title":"World J Gastroenterol"},{"key":"4695_CR10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2011.01.051","volume":"140","author":"JF Rehfeld","year":"2011","unstructured":"Rehfeld JF, Gingras M, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger\u2013Ellison syndrome and mismeasurement of gastrin. Gastroenterology. 2011;140:1444\u20131453.","journal-title":"Gastroenterology"},{"key":"4695_CR11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0016-5085(95)90124-8","volume":"108","author":"HC Weber","year":"1995","unstructured":"Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger\u2013Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637\u20131649.","journal-title":"Gastroenterology"},{"key":"4695_CR12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.surg.2015.11.010","volume":"159","author":"XM Keutgen","year":"2016","unstructured":"Keutgen XM, Nilubol N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: a survival analysis. Surgery. 2016;159:1382\u20131389.","journal-title":"Surgery"},{"key":"4695_CR13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1046\/j.1365-2036.2001.01085.x","volume":"15","author":"VD Corleto","year":"2001","unstructured":"Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and\/or delay the diagnosis of Zollinger\u2013Ellison syndrome? Aliment Pharmacol Ther. 2001;15:1555\u20131561.","journal-title":"Aliment Pharmacol Ther"},{"key":"4695_CR14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cncr.11473","volume":"98","author":"A Abou-Saif","year":"2003","unstructured":"Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer. 2003;98:249\u2013261.","journal-title":"Cancer"},{"key":"4695_CR15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/cas.12533","volume":"105","author":"M Hijioka","year":"2014","unstructured":"Hijioka M, Ito T, Igarashi H, et al. Serum chromogranin A is a useful marker for japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464\u20131471.","journal-title":"Cancer Sci"},{"key":"4695_CR16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/MNM.0b013e328347a895","volume":"32","author":"M Stokkel","year":"2011","unstructured":"Stokkel M, Rietbergen D, Korse C, Taal B. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Nucl Med Commun. 2011;32:731\u2013737.","journal-title":"Nucl Med Commun"},{"key":"4695_CR17","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","volume":"25","author":"D Campana","year":"2007","unstructured":"Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967\u20131973.","journal-title":"J Clin Oncol"},{"key":"4695_CR18","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","volume":"17","author":"I Modlin","year":"2010","unstructured":"Modlin I, Gustafsson B, Moss S, Pavel M, Tsolakis A, Kidd M. Chromogranin A\u2014biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427\u20132443.","journal-title":"Ann Surg Oncol"},{"key":"4695_CR19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/archsurg.1995.01430040029003","volume":"130","author":"I Modlin","year":"1995","unstructured":"Modlin I, Cornelius E, Lawton GP. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg. 1995;130:367\u2013373.","journal-title":"Arch Surg"},{"key":"4695_CR20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735\u2013752.","journal-title":"Pancreas"},{"key":"4695_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00000658-199808000-00013","volume":"228","author":"HR Alexander","year":"1998","unstructured":"Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger\u2013Ellison syndrome. Ann Surg. 1998;228:228\u2013238.","journal-title":"Ann Surg"},{"key":"4695_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/radiology.214.2.r00fe32483","volume":"214","author":"RF Thoeni","year":"2000","unstructured":"Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214:483\u2013490.","journal-title":"Radiology"},{"key":"4695_CR23","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","volume":"95","author":"MA Anderson","year":"2000","unstructured":"Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271\u20132277.","journal-title":"Am J Gastroenterol"},{"key":"4695_CR24","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJM199206253262601","volume":"326","author":"T R\u00f6sch","year":"1992","unstructured":"R\u00f6sch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721\u20131726.","journal-title":"N Engl J Med"},{"key":"4695_CR25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/01.sla.0000143252.02142.3e","volume":"240","author":"JA Norton","year":"2004","unstructured":"Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger\u2013Ellison syndrome. Ann Surg. 2004;240:757\u2013773.","journal-title":"Ann Surg"},{"key":"4695_CR26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","volume":"41","author":"D Raines","year":"2012","unstructured":"Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41:508\u2013511.","journal-title":"Pancreas"},{"key":"4695_CR27","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kj\u00e6r A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259\u20132277.","journal-title":"Future Oncol"},{"key":"4695_CR28","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2006.08.040","volume":"131","author":"KA Smith","year":"2006","unstructured":"Smith KA, Patel O, Lachal S, et al. Production, secretion, and biological activity of the C-terminal flanking peptide of human progastrin. Gastroenterology. 2006;131:1463\u20131474.","journal-title":"Gastroenterology"},{"key":"4695_CR29","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00172.2006","volume":"291","author":"RN Jain","year":"2006","unstructured":"Jain RN, Samuelson LC. Differentiation of the gastric mucosa II. Role of gastrin in gastric epithelial cell proliferation and maturation. Am J Physiol Gastrointest Liver Physiol. 2006;291:G762\u2013G765.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4695_CR30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/gast.2002.34231","volume":"123","author":"PL Peghini","year":"2002","unstructured":"Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68\u201385.","journal-title":"Gastroenterology"},{"key":"4695_CR31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0016-5085(90)90611-4","volume":"99","author":"PN Maton","year":"1990","unstructured":"Maton PN, Lack EE, Collen MJ, et al. The effect of Zollinger\u2013Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology. 1990;99:943\u2013950.","journal-title":"Gastroenterology"},{"key":"4695_CR32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/BF02088045","volume":"39","author":"MJ Collen","year":"1994","unstructured":"Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Dig Dis Sci. 1994;39:1434\u20131440.","journal-title":"Dig Dis Sci"},{"key":"4695_CR33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/den.12427","volume":"5","author":"W Hatta","year":"2015","unstructured":"Hatta W, Iijima K, Koike T, et al. Endoscopic findings for predicting gastric acid secretion status. Dig Endosc. 2015;5:582\u2013589.","journal-title":"Dig Endosc"},{"key":"4695_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/SLA.0b013e31815efda5","volume":"247","author":"JA Norton","year":"2008","unstructured":"Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger\u2013Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247:501\u2013510.","journal-title":"Ann Surg"},{"key":"4695_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.md.0000112297.72510.32","volume":"83","author":"F Gibril","year":"2004","unstructured":"Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger\u2013Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine. 2004;83:43\u201383.","journal-title":"Medicine"},{"key":"4695_CR36","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","volume":"97","author":"RV Thakker","year":"2012","unstructured":"Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990\u20133011.","journal-title":"J Clin Endocrinol Metab"},{"key":"4695_CR37","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1210\/jcem.85.11.6963","volume":"85","author":"SU Goebel","year":"2000","unstructured":"Goebel SU, Peghini PL, Goldsmith PK, et al. Expression of the calcium-sensing receptor in gastrinomas. J Clin Endocrinol Metab. 2000;85:4131\u20134137.","journal-title":"J Clin Endocrinol Metab"},{"key":"4695_CR38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","volume":"101","author":"JM Scheiman","year":"2006","unstructured":"Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701\u2013710.","journal-title":"Am J Gastroenterol"},{"key":"4695_CR39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","volume":"338","author":"CJ Hawkey","year":"1998","unstructured":"Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:727\u2013734.","journal-title":"N Engl J Med"},{"key":"4695_CR40","first-page":"1409","volume":"93","author":"L Laine","year":"1998","unstructured":"Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the united states been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 1998;93:1409\u20131415.","journal-title":"Am J Gastroenterol"},{"key":"4695_CR41","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","volume":"118","author":"MM Wolfe","year":"2000","unstructured":"Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9\u2013S31.","journal-title":"Gastroenterology"},{"key":"4695_CR42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2006.02762.x","volume":"23","author":"DC Metz","year":"2006","unstructured":"Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger\u2013Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23:437\u2013444.","journal-title":"Aliment Pharmacol Ther"},{"key":"4695_CR43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1572-0241.2003.07262.x","volume":"98","author":"DC Metz","year":"2003","unstructured":"Metz DC, Soffer E, Forsmark CE, et al. Maintenance oral pantoprazole therapy is effective for patients with Zollinger\u2013Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003;98:301\u2013307.","journal-title":"Am J Gastroenterol"},{"key":"4695_CR44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2036.1996.tb00178.x","volume":"10","author":"B Termanini","year":"1996","unstructured":"Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger\u2013Ellison syndrome. Aliment Pharmacol Ther. 1996;10:61\u201371.","journal-title":"Aliment Pharmacol Ther"},{"key":"4695_CR45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","volume":"85","author":"MJ Berna","year":"2006","unstructured":"Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the national institutes of health and comparison with 2229 cases from the literature. Medicine. 2006;85:295\u2013330.","journal-title":"Medicine"},{"key":"4695_CR46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00005792-200105000-00005","volume":"80","author":"PK Roy","year":"2001","unstructured":"Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis\u2014a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine. 2001;80:189\u2013222.","journal-title":"Medicine"},{"key":"4695_CR47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11938-015-0065-8","volume":"13","author":"J Phan","year":"2015","unstructured":"Phan J, Benhammou J, Pisegna J. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015;13:386\u2013397.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"4695_CR48","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.cgh.2006.08.015","volume":"4","author":"DS Oh","year":"2006","unstructured":"Oh DS, Wang HS, Ohning GV, Pisegna JR. Validation of a new endoscopic technique to assess acid output in Zollinger\u2013Ellison syndrome. Clin Gastroenterol Hepatol. 2006;4:1467\u20131473.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4695_CR49","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/apt.12325","volume":"37","author":"DH Weinstein","year":"2013","unstructured":"Weinstein DH, deRijke S, Chow CC, et al. A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther. 2013;37:1198\u20131209.","journal-title":"Aliment Pharmacol Ther"},{"key":"4695_CR50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.7326\/0003-4819-111-9-713","volume":"111","author":"H Frucht","year":"1989","unstructured":"Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger\u2013Ellison syndrome. A prospective study. Ann Intern Med. 1989;111:713\u2013722.","journal-title":"Ann Intern Med"},{"key":"4695_CR51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MD.0b013e31802b518c","volume":"85","author":"MJ Berna","year":"2006","unstructured":"Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature: evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine. 2006;85:331\u2013364.","journal-title":"Medicine"},{"key":"4695_CR52","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2036.2001.00976.x","volume":"15","author":"DC Metz","year":"2001","unstructured":"Metz DC, Buchanan M, Purich E, Fein S. A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger\u2013Ellison syndrome. Aliment Pharmacol Ther. 2001;15:669\u2013676.","journal-title":"Aliment Pharmacol Ther"},{"key":"4695_CR53","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1210\/jc.2007-0986","volume":"92","author":"SH Long","year":"2007","unstructured":"Long SH, Berna MJ, Thill M, et al. Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab. 2007;92:4394\u20134402.","journal-title":"J Clin Endocrinol Metab"},{"key":"4695_CR54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/MPA.0b013e3182847b2e","volume":"42","author":"P Shah","year":"2013","unstructured":"Shah P, Singh MH, Yang Y, Metz DC. Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger\u2013Ellison syndrome. Pancreas. 2013;42:932\u2013936.","journal-title":"Pancreas"},{"key":"4695_CR55","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1053\/gast.2002.36593","volume":"123","author":"JM Shin","year":"2002","unstructured":"Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002;123:1588\u20131597.","journal-title":"Gastroenterology"},{"key":"4695_CR56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF03189822","volume":"23","author":"M Katashima","year":"1998","unstructured":"Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic\/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet. 1998;23:19\u201326.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4695_CR57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cgh.2011.08.012","volume":"10","author":"P Poitras","year":"2012","unstructured":"Poitras P, Gingras MH, Rehfeld JF. The Zollinger\u2013Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10:199\u2013202.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4695_CR58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2016.11.035","volume":"130","author":"N Singh Ospina","year":"2017","unstructured":"Singh Ospina N, Donegan D, Rodriguez-Gutierrez R, Al-Hilli Z, Young WF. Assessing for multiple endocrine neoplasia type 1 in patients evaluated for Zollinger\u2013Ellison syndrome\u2014clues to a safer diagnostic process. Am J Med. 2017;130:603\u2013605.","journal-title":"Am J Med"},{"key":"4695_CR59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0773.2001.d01-161.x","volume":"89","author":"D Gillen","year":"2001","unstructured":"Gillen D, McColl KE. Problems associated with the clinical use of proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2001;89:281\u2013286.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4695_CR60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2006.pto_378.x","volume":"98","author":"RT Jensen","year":"2006","unstructured":"Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4\u201319.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4695_CR61","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","volume":"39","author":"HL Waldum","year":"1996","unstructured":"Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649\u2013653.","journal-title":"Gut"},{"key":"4695_CR62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/edrv-12-2-181","volume":"12","author":"LJ Deftos","year":"1991","unstructured":"Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181\u2013188.","journal-title":"Endocr Rev"},{"key":"4695_CR63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00042737-200101000-00010","volume":"13","author":"P Tomassetti","year":"2001","unstructured":"Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13:55\u201358.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4695_CR64","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1470::AID-CNCR7>3.0.CO;2-S","volume":"85","author":"SU Goebel","year":"1999","unstructured":"Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470\u20131483.","journal-title":"Cancer"},{"key":"4695_CR65","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cen.13119","volume":"85","author":"W Qiu","year":"2016","unstructured":"Qiu W, Christakis I, Silva A, et al. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol. 2016;85:400\u2013407.","journal-title":"Clin Endocrinol"},{"key":"4695_CR66","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archsurg.2012.1261","volume":"147","author":"GW Krampitz","year":"2012","unstructured":"Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820\u2013827.","journal-title":"Arch Surg"},{"key":"4695_CR67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jso.22118","volume":"105","author":"CL Roland","year":"2012","unstructured":"Roland CL, Bian A, Mansour JC, et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol. 2012;105:595\u2013600.","journal-title":"J Surg Oncol"},{"key":"4695_CR68","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s11605-015-3015-9","volume":"20","author":"EH Twerdahl","year":"2016","unstructured":"Twerdahl EH, Costantino CL, Ferrone CR, Hodin RA. Primary hepatic gastrinoma. J Gastrointest Surg. 2016;20:662\u2013663.","journal-title":"J Gastrointest Surg"},{"key":"4695_CR69","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0016-5085(87)90963-2","volume":"92","author":"SA Wank","year":"1987","unstructured":"Wank SA, Doppman JL, Miller DL, et al. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger\u2013Ellison syndrome. Gastroenterology. 1987;92:905\u2013912.","journal-title":"Gastroenterology"},{"key":"4695_CR70","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1102\/1470-7330.2006.9037","volume":"6","author":"RH Reznek","year":"2006","unstructured":"Reznek RH. CT\/MRI of neuroendocrine tumours. Cancer Imaging. 2006;6:S163\u2013S177.","journal-title":"Cancer Imaging"},{"key":"4695_CR71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-125-1-199607010-00005","volume":"125","author":"F Gibril","year":"1996","unstructured":"Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med. 1996;125:26\u201334.","journal-title":"Ann Intern Med"},{"key":"4695_CR72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdg279","volume":"14","author":"M Cimitan","year":"2003","unstructured":"Cimitan M, Buonadonna A, Cannizzaro R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135\u20131141.","journal-title":"Ann Oncol"},{"key":"4695_CR73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2003.01885.x","volume":"59","author":"Y Krausz","year":"2003","unstructured":"Krausz Y, Keidar Z, Kogan I, et al. SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol. 2003;59:565\u2013573.","journal-title":"Clin Endocrinol"},{"key":"4695_CR74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2967\/jnumed.115.161117","volume":"57","author":"J Ruf","year":"2016","unstructured":"Ruf J, Wedel FV, Christian F, et al. Significance of a single-time-point somatostatin receptor SPECT\/multiphase CT protocol in the diagnostic work-up of gastroenteropancreatic neuroendocrine neoplasms. J Nucl Med. 2016;57:180\u2013185.","journal-title":"J Nucl Med"},{"key":"4695_CR75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4329\/wjr.v8.i6.635","volume":"8","author":"KK Wong","year":"2016","unstructured":"Wong KK, Ghandi A, Viglianti BL, Fig LM, Rubello D, Gross MD. Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography\/computed tomography. World J Radiol. 2016;8:635\u2013655.","journal-title":"World J Radiol"},{"key":"4695_CR76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MNM.0000000000000239","volume":"36","author":"A Sainz-Esteban","year":"2015","unstructured":"Sainz-Esteban A, Olmos R, Gonz\u00e1lez-Sagrado M, et al. Contribution of 111In-pentetreotide SPECT\/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Nucl Med Commun. 2015;36:251\u2013259.","journal-title":"Nucl Med Commun"},{"key":"4695_CR77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, et al. 68\u00a0Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508\u2013518.","journal-title":"J Nucl Med"},{"key":"4695_CR78","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, et al. Comparison of 68\u00a0Ga-DOTANOC and 68\u00a0Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364\u2013372.","journal-title":"J Nucl Med"},{"key":"4695_CR79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.114.148247","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Czernin J, Wolin EM, et al. Impact of 68\u00a0Ga-DOTATATE PET\/CT on the management of neuroendocrine tumors: the referring physician\u2019s perspective. J Nucl Med. 2015;56:70\u201375.","journal-title":"J Nucl Med"},{"key":"4695_CR80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","volume":"57","author":"E Skoura","year":"2016","unstructured":"Skoura E, Michopoulou S, Mohmaduvesh M, et al. The impact of 68\u00a0Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med. 2016;57:34\u201340.","journal-title":"J Nucl Med"},{"key":"4695_CR81","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/RLU.0000000000000257","volume":"39","author":"P Sharma","year":"2014","unstructured":"Sharma P, Arora S, Mukherjee A, et al. Predictive value of 68\u00a0Ga-DOTANOC PET\/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Clin Nucl Med. 2014;39:37\u201343.","journal-title":"Clin Nucl Med"},{"key":"4695_CR82","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","volume":"40","author":"H Geijer","year":"2013","unstructured":"Geijer H, Breimer L. Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770\u20131780.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4695_CR83","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2967\/jnumed.108.060236","volume":"50","author":"D Putzer","year":"2009","unstructured":"Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68\u00a0Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214\u20131221.","journal-title":"J Nucl Med"},{"key":"4695_CR84","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.192450","author":"J Calais","year":"2017","unstructured":"Calais J, Czernin J, Eiber M, et al. Most intended management changes after 68Ga-DOTATE PET\/CT are implemented. J Nucl Med. 2017. doi:\n                        10.2967\/jnumed.117.192450\n                        \n                    .","journal-title":"J Nucl Med"},{"key":"4695_CR85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1572-0241.2006.00367.x","volume":"101","author":"L Thomas-Marques","year":"2006","unstructured":"Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol. 2006;101:266\u2013273.","journal-title":"Am J Gastroenterol"},{"key":"4695_CR86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1067\/S0016-5107(03)01965-5","volume":"58","author":"E Wamsteker","year":"2003","unstructured":"Wamsteker E, Gauger PG, Thompson NW, Scheiman JM. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc. 2003;58:531\u2013535.","journal-title":"Gastrointest Endosc"},{"key":"4695_CR87","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.dld.2011.09.014","volume":"44","author":"C Barbe","year":"2012","unstructured":"Barbe C, Murat A, Dupas B, et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis. 2012;44:228\u2013234.","journal-title":"Dig Liver Dis"},{"key":"4695_CR88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0042-119402","volume":"49","author":"W Kappelle","year":"2016","unstructured":"Kappelle W, Valk G, Leenders M, et al. Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. Endoscopy. 2016;49:27\u201334.","journal-title":"Endoscopy"},{"key":"4695_CR89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2303-9027.200213","volume":"6","author":"B Braden","year":"2017","unstructured":"Braden B, Jenssen C, D\u2019Onofrio M, et al. B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors. Endosc Ultrasound. 2017;6:49\u201354.","journal-title":"Endosc Ultrasound"},{"key":"4695_CR90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.gie.2014.09.037","volume":"81","author":"SJ Asselt van","year":"2015","unstructured":"van Asselt SJ, Brouwers AH, Dullemen HM, et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc. 2015;81:159\u2013167.","journal-title":"Gastrointest Endosc"},{"key":"4695_CR91","first-page":"1","volume":"4","author":"J Wang","year":"2017","unstructured":"Wang J, Benhammou JN, Ghassemi K, et al. Endoscopic ultrasound-guided fine needle aspiration accurately diagnoses smaller pancreatic neuroendocrine tumors compared to computer tomography-guided fine needle aspiration. J Gastroenterol Pancreatol Liver Disord. 2017;4:1\u20137.","journal-title":"J Gastroenterol Pancreatol Liver Disord"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4695-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T12:01:45Z","timestamp":1502884905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["4695"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4695-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}